Novo Nordisk invests into its Athlone facility transforming it into a key  production site for oral GLP-1 treatments.

Novo Nordisk is investing over €400 million to expand its Athlone facility — transforming it into a key global hub for the production of oral GLP-1 treatments, including tablet forms of Wegovy. This marks a significant shift for the site — moving into high-volume oral solid dose manufacturing to support growing global demand.

But with that scale comes complexity

🔷New production lines and tableting capabilities
🔷Increased throughput and batch volumes
🔷More assets, systems, and dependencies across the site

Greater pressure on coordination between production, engineering, and EHSAs facilities expand, the challenge isn’t just adding capacity — it’s maintaining clarity across everything that supports it.
‍
🔷Where are critical assets located?
🔷How are systems connected?
🔷What is impacted when something changes?

At this level of scale, operational visibility becomes essential. Growth without clarity introduces risk, and clarity is what allows complex facilities to operate with confidence.

At PlantQuest, we’re proud to spotlight initiatives that drive global pharmaceutical innovation. We look forward to continuing to support forward-thinking organisations as they set new benchmarks.